<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordsOutput xmlns:ns2="local"><serviceExecutionTime>350</serviceExecutionTime><Drug id="53632"><DrugName>ALN-HBV</DrugName><DrugSynonyms><Name><Value>hepatitis B virus therapy, Sirna</Value></Name><Name><Value>hepatitis B virus siRNA, Sirna</Value></Name><Name><Value>RNAi therapy (hepatitis B virus), Sirna</Value></Name><Name><Value>siRNA therapy (HBV infection), Sirna</Value></Name><Name><Value>RNAi therapy (hepatitis B virus), Merck &amp; Co</Value></Name><Name><Value>siRNA therapy (HBV infection), Merck &amp; Co</Value></Name><Name><Value>ALN-HBV</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>RNAi therapy (sc, HBV infection), Alnylam Pharmaceuticals</Value></Name><Name><Value>ALN-HBV-DC</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="19440">Sirna Therapeutics Inc</CompanyOriginator><CompaniesSecondary><Company id="18077">Merck &amp; Co Inc</Company><Company id="19440">Sirna Therapeutics Inc</Company><Company id="29927">Alnylam Pharmaceuticals Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="18077" type="Company"><TargetEntity id="4295904886" type="organizationId">Merck &amp; Co Inc</TargetEntity></SourceEntity><SourceEntity id="19440" type="Company"><TargetEntity id="4295907786" type="organizationId">Sirna Therapeutics Inc</TargetEntity></SourceEntity><SourceEntity id="29927" type="Company"><TargetEntity id="4295916167" type="organizationId">Alnylam Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="152" type="ciIndication"><TargetEntity id="10019731" type="MEDDRA"></TargetEntity><TargetEntity id="D019694" type="MeSH"></TargetEntity><TargetEntity id="-1284790527" type="omicsDisease"></TargetEntity><TargetEntity id="429" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="991" type="Action"><TargetEntity id="4479" type="Mechanism">Drugs Targeting JC Polyomavirus Proteins</TargetEntity><TargetEntity id="5287" type="Mechanism">Drugs Targeting Influenza Virus Proteins</TargetEntity><TargetEntity id="3371" type="Mechanism">Drugs Acting on Influenza Virus Proton Channels</TargetEntity><TargetEntity id="3759" type="Mechanism">L Expression Inhibitors</TargetEntity><TargetEntity id="1376" type="Mechanism">BR1 Expression Inhibitors</TargetEntity><TargetEntity id="3235" type="Mechanism">UL29 Expression Inhibitors</TargetEntity><TargetEntity id="2893" type="Mechanism">Human T-Cell Leukemia Virus Type I (HTLV-I) Protease Inhibitors</TargetEntity><TargetEntity id="4886" type="Mechanism">Drugs Targeting Hepatitis C Virus (HCV) Proteins</TargetEntity><TargetEntity id="1307" type="Mechanism">Viral Fusion Inhibitors</TargetEntity><TargetEntity id="3575" type="Mechanism">Orthopoxvirus Egress Inhibitors</TargetEntity><TargetEntity id="4128" type="Mechanism">Flavivirus Guanylyl Transferase (NS5) Inhibitors</TargetEntity><TargetEntity id="4476" type="Mechanism">Anti-JC Polyomavirus Capsid Protein</TargetEntity><TargetEntity id="3481" type="Mechanism">UL36 Expression Inhibitors</TargetEntity><TargetEntity id="3482" type="Mechanism">UL37 Expression Inhibitors</TargetEntity><TargetEntity id="3051" type="Mechanism">Viral Attachment Inhibitors</TargetEntity><TargetEntity id="2436" type="Mechanism">Viral Maturation Inhibitors</TargetEntity><TargetEntity id="4612" type="Mechanism">Drugs Targeting Human Immunodeficiency Virus 1 (HIV-1) Proteins</TargetEntity><TargetEntity id="5304" type="Mechanism">Drugs Targeting Rabies Virus Proteins</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C2">Phase 2 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="152">Hepatitis B virus infection</Indication></IndicationsSecondary><ActionsSecondary><Action id="59620">Unspecified drug target</Action><Action id="991">Antiviral</Action><Action id="26035">siRNA agent</Action></ActionsSecondary><Technologies><Technology id="103">Oligonucleotide</Technology><Technology id="647">Subcutaneous formulation</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="761">Biological therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>J5</Code><Name>ANTIVIRALS FOR SYSTEMIC USE</Name></Ephmra></EphmraCodes><LastModificationDate>2018-05-02T07:28:14.000Z</LastModificationDate><ChangeDateLast>2017-10-20T00:00:00.000Z</ChangeDateLast><AddedDate>2005-07-26T10:29:27.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="29927" linkType="Company"&gt;Alnylam Pharmaceuticals&lt;/ulink&gt; following its acquisition of &lt;ulink linkID="19440" linkType="Company"&gt;Sirna Therapeutics&lt;/ulink&gt; from &lt;ulink linkID="18077" linkType="Company"&gt;Merck &amp;amp; Co&lt;/ulink&gt;, was developing ALN-HBV (ALN-HBV-DC), a lead from a program of RNAi therapeutics targeting the HBV genome, developed using Enhanced Stabilization Chemistry - GalNAc-conjugate technology, for the potential sc treatment of hepatitis B virus (HBV) infection [&lt;ulink linkID="1555886" linkType="Reference"&gt;1555886&lt;/ulink&gt;], [&lt;ulink linkID="1568728" linkType="Reference"&gt;1568728&lt;/ulink&gt;], [&lt;ulink linkID="1620492" linkType="Reference"&gt;1620492&lt;/ulink&gt;], [&lt;ulink linkID="1778937" linkType="Reference"&gt;1778937&lt;/ulink&gt;], [&lt;ulink linkID="1778907" linkType="Reference"&gt;1778907&lt;/ulink&gt;]. In July 2016, a phase I/II trial was initiated in the UK [&lt;ulink linkID="1778937" linkType="Reference"&gt;1778937&lt;/ulink&gt;], [&lt;ulink linkID="1778907" linkType="Reference"&gt;1778907&lt;/ulink&gt;]; however, in October 2017, Alnylam discontinued further development of ALN-HBV [&lt;ulink linkID="1972359" linkType="Reference"&gt;1972359&lt;/ulink&gt;]. In January 2016, the company intended on seeking to outlicense the drug outside the US and EU [&lt;ulink linkID="1726386" linkType="Reference"&gt;1726386&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In August 2015, a Clinical Trial Application (CTA) was expected to be filed in late 2015 [&lt;ulink linkID="1684493" linkType="Reference"&gt;1684493&lt;/ulink&gt;]. In December 2015, the CTA filing was expected  in early 2016Â [&lt;ulink linkID="1720342" linkType="Reference"&gt;1720342&lt;/ulink&gt;]. In January 2016, a phase I trial was planned to begin in mid-2016 [&lt;ulink linkID="1726386" linkType="Reference"&gt;1726386&lt;/ulink&gt;]. By May 2016, CTA had been filed [&lt;ulink linkID="1758058" linkType="Reference"&gt;1758058&lt;/ulink&gt;]. In July 2016, a  randomized, single-blind, placebo-controlled, single- and multiple-ascending dose, phase I/II trial (&lt;ulink linkID="265144" linkType="Protocol"&gt;NCT02826018&lt;/ulink&gt;; ALN-HBV-001) to evaluate the safety and efficacy of ALN-HBV in patients (expected n = 112) with chronic HBV infection was initiated in Australia, Hong Kong,  New Zealand, Singapore, and the UK. The trial would be split into three parts; Part A would be a single-dose study in 24 healthy volunteers, Part B would be a single-dose study in 28 chronic HBV patients, and Part C would be a multi-dose study in up to 48 chronic HBV patients. At that time, the trial was expected to complete in April 2018 [&lt;ulink linkID="1778937" linkType="Reference"&gt;1778937&lt;/ulink&gt;], [&lt;ulink linkID="1778907" linkType="Reference"&gt;1778907&lt;/ulink&gt;]. In November 2016, the protocol was approved in Korea [&lt;ulink linkID="1731113" linkType="Reference"&gt;1731113&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2014, the company planned to  advance &lt;ulink linkID="93572" linkType="Drug"&gt;ALN-HDV&lt;/ulink&gt; as an ESC-GalNAc-siRNA conjugate combination with ALN-HBV targeting both the HBV and HDV genomes [&lt;ulink linkID="1611067" linkType="Reference"&gt;1611067&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In November 2015, preclinical data were presented at AASLD's Liver Meeting 2015 in San Francisco, CA. Viral transcript silencing was mediated by ALN-HBV with ED50 values ranging from 12 to 19 pM for amplicons in the P and S open reading frame in HepG2.2.15 cells. In an AAV-HBV mouse model, a single sc dose of ANL-HBV (3 mg/kg) led to a mean 1.6 log10 reduction in plasma HB surface antigen (HBsAg) at 10 to 15 days post-dosing. Excellent tolerability was observed after three weekly doses of 30 and 100 mg/kg in rats sacrificed 24 h after 3 weekly doses of ALN-HBV (30 and 100 mg/kg) [&lt;ulink linkID="1712980" linkType="Reference"&gt;1712980&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2014, preclinical data from a rodent model were reported. Data demonstrated that a dose at 3 mg/kg resulted in an up to 3.9 log10 reduction in hepatitis B surface antigen (HBsAg) levels (mean 1.8 log10 reduction) [&lt;ulink linkID="1620492" linkType="Reference"&gt;1620492&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2014, preclinical data were presented at The Liver Meeting 2014 in Boston, MA. Dose-dependent mean 2.9 log10 decrease in viral DNA at 0.5 mg/kg dose and &amp;gt; 4 log10 reduction in circulating viral DNA was observed in highest titer animal and mean 2.0 up to 2.3 log10 reduction in HBsAg at 0.5 mg/kg dose reduction was observed [&lt;ulink linkID="1606691" linkType="Reference"&gt;1606691&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2014, preclinical, proof of concept data from a study conducted in chronically infected chimpanzees (n = 4) model were presented at the TIDES 2014 meeting in Providence, Rhode Island. Data showed an over 2 log10 decrease in circulating viral DNA in the highest titer animal with a mean 1.9 log10 decrease in viral DNA, following a single 0.25 mg/kg dose. In multi-dose, dose-escalation studies, doses of 0.125 to 0.5 mg/kg achieved an over 4 log10 reduction of circulating viral DNA and up to 2.3 log10 reduction in HBsAg, a mean 2.9 log10 reduction and a mean 2.0 log10 reduction were achieved in HBV DNA and HBsAg, respectively. Complete normalization of elevated alanine aminotransferase (ALT) levels by the RNAi therapeutic was noted in one animal which had greater than 5-fold elevated ALT levels at baseline. After one-to-two months post dosing, two of four animals observed to have mildly elevated liver transaminase levels of about two-to-three fold, with increased interferon-gamma and IL-6 [&lt;ulink linkID="1555886" linkType="Reference"&gt;1555886&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2006, preclinical data were presented at the 231st ACS meeting in Atlanta, GA. Lipid nanoparticles formulated with siRNA exhibited an IC50 value of approximately 1 nM in vitro and displayed dose-dependent efficacy in an HBV mouse model (serum HBV DNA). In an experiment determining the reduction of liver HBV RNA, there was a 95% knockdown in the liver of treated animals. Further data presented at this meeting showed that when adefovir dipivoxil was used in combination with siRNA in a transgenic mouse model, a dose of 3 mg/kg/day given for 4 days resulted in a 10-fold increase in activity compared with the individual components in the liver HBV DNA [&lt;ulink linkID="658172" linkType="Reference"&gt;658172&lt;/ulink&gt;], [&lt;ulink linkID="657091" linkType="Reference"&gt;657091&lt;/ulink&gt;]. The siRNA stability in 90% human serum was determined in labeled ribose and non-ribose strands. In the modified (all ribose) strand, the t1/2 was 1.5 and 1.7 min in the sense and antisense strands, respectively, and 5.5 and 4.0 days, respectively, in the unmodified (non-ribose) strand. In an HBV siRNA duration of effect study, chemical modification was required for the duration of activity. Inhibition in HBsAg was greatest in stabilized siRNA, followed by partially stabilized siRNA and lowest in RNA when administered as a single dose of 100 nM on day 1. Activity was lost over time in all RNA, partially stabilized and fully stabilized RNA. Chemical modifications improved plasma pharmacokinetics in mice. At a single iv dose of 30 mg/kg, t1/2 was 1.5, 16 and 49 min in RNA, partially stabilized siRNA and fully stabilized siRNA. Pharmacokinetic studies in mice with lipid nanoparticle-formulated modified siRNA showed that the molecules entered the liver and were stillÂ detectable in the liver by day 15 [&lt;ulink linkID="657091" linkType="Reference"&gt;657091&lt;/ulink&gt;]. Similar data were reported in May 2006, at TIDES 2006 in Carlsbad, CA [&lt;ulink linkID="667442" linkType="Reference"&gt;667442&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In November 2005, preclinical data were presented at SRI's Third Annual Nucleic Acid World Summit in Cambridge, MA. Intravenous delivery of 2'-ribose-modified siRNAs (10 to 30 mg/kg)  reduced viral infection when injected into HBV-infected mice at 6 days post-infection (compared to native RNA)  [&lt;ulink linkID="635740" linkType="Reference"&gt;635740&lt;/ulink&gt;]. Further data were also presented that month at the 56th AASLD meeting in San Francisco, CA. Administration three times daily (3 mg/kg iv), in HBV-infected mice showed a dose-dependent effect that persisted for 14 days after dosing. Mice showed a 3-log reduction in viral DNA levels compared to controls as well as siRNA-mediated reduction of virus RNA in the liver. Cytokine levels were not increased [&lt;ulink linkID="642943" linkType="Reference"&gt;642943&lt;/ulink&gt;]. In January 2006, further murine data presented at JP Morgan's 24th Annual Healthcare Conference in San Francisco, CA, showed that administration of 3 mg/kg/day siRNA for 3 days reduced serum HCV levels by 99.9% after 7 days [&lt;ulink linkID="645297" linkType="Reference"&gt;645297&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2005,  data were published demonstrating a 95% knockdown of HBV, which persisted for at least 7 days in mice who received the siRNA formulation by standard iv injection [&lt;ulink linkID="613865" linkType="Reference"&gt;613865&lt;/ulink&gt;]. &lt;br&gt;&lt;/br&gt;In June 2005, data from a surrogate HBV mouse model was published, showing that standard iv injection reduced HBV DNA serum levels in mice by 1 log10. High volume tail injection caused a 3 log10 decrease in levels of serum HBV DNA, as well as liver HBV RNA. The observed decrease in serum HBV DNA was1.5 log10 greater with a modified siRNA than with an unmodified siRNA [&lt;ulink linkID="605922" linkType="Reference"&gt;605922&lt;/ulink&gt;], [&lt;ulink linkID="614132" linkType="Reference"&gt;614132&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="29927">Alnylam Pharmaceuticals Inc</Company><Country id="HK">Hong Kong</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="152">Hepatitis B virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-10-18T00:00:00.000Z</StatusDate><Source id="1972359" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29927">Alnylam Pharmaceuticals Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="152">Hepatitis B virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-10-18T00:00:00.000Z</StatusDate><Source id="1972359" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29927">Alnylam Pharmaceuticals Inc</Company><Country id="SG">Singapore</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="152">Hepatitis B virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-10-18T00:00:00.000Z</StatusDate><Source id="1972359" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29927">Alnylam Pharmaceuticals Inc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="152">Hepatitis B virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-10-18T00:00:00.000Z</StatusDate><Source id="1972359" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29927">Alnylam Pharmaceuticals Inc</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="152">Hepatitis B virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-10-18T00:00:00.000Z</StatusDate><Source id="1972359" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29927">Alnylam Pharmaceuticals Inc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="152">Hepatitis B virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-10-18T00:00:00.000Z</StatusDate><Source id="1972359" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="29927">Alnylam Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="152">Hepatitis B virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-05-12T00:00:00.000Z</StatusDate><Source id="1555886" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29927">Alnylam Pharmaceuticals Inc</Company><Country id="HK">Hong Kong</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="152">Hepatitis B virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-07-07T00:00:00.000Z</StatusDate><Source id="1778937" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29927">Alnylam Pharmaceuticals Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="152">Hepatitis B virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-07-07T00:00:00.000Z</StatusDate><Source id="1778937" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29927">Alnylam Pharmaceuticals Inc</Company><Country id="GB">UK</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="152">Hepatitis B virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-07-07T00:00:00.000Z</StatusDate><Source id="1778937" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29927">Alnylam Pharmaceuticals Inc</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="152">Hepatitis B virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-07-07T00:00:00.000Z</StatusDate><Source id="1778937" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29927">Alnylam Pharmaceuticals Inc</Company><Country id="SG">Singapore</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="152">Hepatitis B virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-07-07T00:00:00.000Z</StatusDate><Source id="1778937" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19440">Sirna Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="152">Hepatitis B virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2005-06-07T00:00:00.000Z</StatusDate><Source id="605922" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="152">Hepatitis B virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-12-31T00:00:00.000Z</StatusDate><Source id="754558" type="PR"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><PatentFamilies><PatentFamily id="2480327" number="WO-03070918" title="RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid"></PatentFamily><PatentFamily id="2480328" number="WO-03072590" title="RNA interference mediated inhibition of MAP kinase genes."></PatentFamily><PatentFamily id="2480331" number="WO-2004111237" title="Rna interference mediated inhibition of platelet-derived endothelial cell growth factor (ecgf1) gene expression using short interfering nucleic acid (sina)"></PatentFamily><PatentFamily id="4014925" number="WO-2016077321" title="Hepatitis B virus (HBV) iRNA compositions and methods of use thereof"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>3</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="SBI Holdings Inc" id="1042185"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Merck &amp; Co Inc" id="18077"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Alnylam Pharmaceuticals Inc" id="29927"></CompanyLink><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordsOutput>